STOCK TITAN

[Form 4] Arcellx, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Heery Christopher, Chief Medical Officer of Arcellx, Inc. (ACLX), reported sales of company common stock under a Rule 10b5-1 trading plan. On 09/18/2025 he sold 3,343 shares at a weighted average price of $80.0085, leaving him with 34,427 shares beneficially owned after that transaction. On 09/19/2025 he sold an additional 300 shares at $80.00, leaving 34,127 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 09/19/2025.

The filing notes the sales were effected pursuant to a 10b5-1 plan entered March 23, 2025, and that the post-transaction totals include 284 shares acquired under the issuer's 2022 Employee Stock Purchase Plan on May 14, 2025. No derivative transactions or other changes were reported.

Il direttore medico di Arcellx, Inc. (ACLX), Heery Christopher, ha comunicato vendite di azioni comuni dell’azienda secondo un piano di trading Rule 10b5-1. Il 18/09/2025 ha venduto 3.343 azioni a un prezzo medio ponderato di $80,0085, lasciando una quota beneficiaria di 34.427 azioni dopo la transazione. Il 19/09/2025 ha venduto ulteriori 300 azioni a $80,00, lasciando 34.127 azioni possedute. Il Modulo 4 è stato firmato da un procuratore il 19/09/2025.

La filing segnala che le vendite sono avvenute ai sensi di un piano 10b5-1 stipulato il 23 marzo 2025, e che i totali post-trasazione includono 284 azioni acquistate nell’Employee Stock Purchase Plan dell’emittente il 14 maggio 2025. Non sono state riportate operazioni su strumenti derivati o altre modifiche.

El Director Médico de Arcellx, Inc. (ACLX), Heery Christopher, informó ventas de acciones comunes de la compañía bajo un plan de negociación Rule 10b5-1. El 18/09/2025 vendió 3.343 acciones a un precio medio ponderado de $80,0085, quedando con 34.427 acciones en beneficio propio tras esa operación. El 19/09/2025 vendió 300 acciones adicionales a $80,00, quedando 34.127 acciones en beneficio propio. El Formulario 4 fue firmado por un apoderado el 19/09/2025.

La presentación señala que las ventas se realizaron conforme a un plan 10b5-1 celebrado el 23 de marzo de 2025, y que los totales tras la operación incluyen 284 acciones adquiridas bajo el Employee Stock Purchase Plan del emisor el 14 de mayo de 2025. No se reportaron transacciones derivadas ni otros cambios.

아셀릭스(Arcellx, Inc. ACLX)의 CMO인 Heery Christopher가 Rule 10b5-1 거래 계획에 따라 회사 보통주를 매도했다고 보고했습니다. 2025년 9월 18일 3,343주를 가중평균가 $80.0085에 매도하여 거래 후 보유주식이 34,427주가 되었습니다. 2025년 9월 19일에는 추가로 300주를 $80.00에 매도하여 보유주식이 34,127주로 감소했습니다. 4형(Form 4)은 2025년 9월 19일에 대리인이 서명했습니다.

보고서에 따르면 매매는 2025년 3월 23일에 체결된 10b5-1 계획에 따라 이루어졌으며, 거래 후 총계에는 2025년 5월 14일에 발행사가 시행한 2022년 직원주식매수계획(Employee Stock Purchase Plan) 하의 284주가 포함됩니다. 파생상품 거래나 기타 변동은 보고되지 않았습니다.

Le directeur médical d’Arcellx, Inc. (ACLX), Heery Christopher, a déclaré des ventes d’actions ordinaires de la société dans le cadre d’un plan de trading Rule 10b5-1. Le 18/09/2025, il a vendu 3 343 actions à un prix moyen pondéré de 80,0085 $, ce qui l’a laissé avec 34 427 actions détenues après cette transaction. Le 19/09/2025, il a vendu 300 actions supplémentaires à 80,00 $, laissant 34 127 actions détenues. Le Formulaire 4 a été signé par un mandataire le 19/09/2025.

Le dépôt précise que les ventes ont été effectuées en vertu d’un plan 10b5-1 établi le 23 mars 2025 et que les totaux post-transaction incluent 284 actions acquises dans le cadre du Employee Stock Purchase Plan de l’émetteur le 14 mai 2025. Aucune transaction dérivée ni autre changement n’a été signalé.

Der Chief Medical Officer von Arcellx, Inc. (ACLX), Heery Christopher, hat Verkäufe von Unternehmensaktien gemäß einem Rule 10b5-1-Handelsplan gemeldet. Am 18.09.2025 verkaufte er 3.343 Aktien zu einem gewichteten Durchschnittspreis von $80,0085, sodass er nach dieser Transaktion 34.427 Aktien im Eigentum hielt. Am 19.09.2025 verkaufte er weitere 300 Aktien zu $80,00, womit sich sein gehaltenes Aktienvolumen auf 34.127 Aktien reduzierte. Das Formular 4 wurde am 19.09.2025 von einem Bevollmächtigten unterzeichnet.

Der Eintrag vermerkt, dass die Verkäufe im Rahmen eines am 23. März 2025 abgeschlossenen 10b5-1-Plans erfolgten und dass die Post-Transaction-Beträge 284 Aktien umfassen, die am 14. Mai 2025 über den Employee Stock Purchase Plan des Emittenten erworben wurden. Es wurden keine Derivategeschäfte oder sonstige Änderungen gemeldet.

أبلغ جِرشيف هاييري Christopher، كبير مسؤولي الطب في Arcellx, Inc. (ACLX) عن مبيعات لأسهم الشركة العادية بموجب خطة تداول وفق Rule 10b5-1. في 18/09/2025 باع 3,343 سهمًا بسعر متوسط مرجّح قدره 80.0085 دولار، ليبقى لديه 34,427 سهمًا مملوكة نيابةً عنه بعد تلك الصفقة. في 19/09/2025 باع 300 سهم إضافي بسعر 80.00 دولار، ليبقى لديه 34,127 سهمًا مملوكة نيابة عنه. تم توقيع النموذج 4 من قبل وكيل قانوني في 19/09/2025.

تشير الإشعار إلى أن المبيعات تمت وفق مخطط 10b5-1 الذي أُبرم في 23 مارس 2025، وأن الإجماليات بعد الصفقة تشمل 284 سهمًا اكتُسبت بموجب برنامج شراء أسهم الموظفين للمُصدر في 14 مايو 2025. لم تُبلغ عن أي معاملات مشتقة أو تغييرات أخرى.

Arcellx, Inc. 的首席医疗官 Heery Christopher 根据 Rule 10b5-1 交易计划报告了公司普通股的出售。 2025年9月18日,他以加权平均价格 $80.0085 出售了 3,343 股,交易后他实际拥有 34,427 股。2025年9月19日,他又以 $80.00 的价格出售了额外的 300 股,实际拥有的股份降至 34,127 股。Form 4 于 2025年9月19日由一名授权代理人签署。

filing 指出销售是根据 2025年3月23日设立的 10b5-1 计划进行的,并且交易后的总数包括在 2025年5月14日通过发行人 2022 年员工股票购买计划获得的 284 股。未报告衍生品交易或其他变动。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Insider sales under a pre-established 10b5-1 plan, modest in size relative to total holdings reported.

The reporting person, the Chief Medical Officer, executed two small open-market disposals totaling 3,643 shares at approximately $80 per share under a 10b5-1 plan dated March 23, 2025. The disclosure clarifies the weighted-average price and that the holdings include recent ESPP-acquired shares. This is a routine compliance disclosure; the 10b5-1 plan provides a non-speculative rationale for the timing of sales. No options, conversions, or other derivative activity are disclosed, and the filings show continued substantial direct ownership.

TL;DR: Governance-wise, the filing is transparent and includes required explanatory detail about the 10b5-1 plan and ESPP shares.

The Form 4 includes the necessary explanations: plan date, weighted-average sale price disclosure, and a note on ESPP shares included in beneficial ownership totals. The form is signed via attorney-in-fact which is properly indicated. There are no unexplained transfers or complex arrangements; presentation is consistent with routine insider-reporting practices.

Il direttore medico di Arcellx, Inc. (ACLX), Heery Christopher, ha comunicato vendite di azioni comuni dell’azienda secondo un piano di trading Rule 10b5-1. Il 18/09/2025 ha venduto 3.343 azioni a un prezzo medio ponderato di $80,0085, lasciando una quota beneficiaria di 34.427 azioni dopo la transazione. Il 19/09/2025 ha venduto ulteriori 300 azioni a $80,00, lasciando 34.127 azioni possedute. Il Modulo 4 è stato firmato da un procuratore il 19/09/2025.

La filing segnala che le vendite sono avvenute ai sensi di un piano 10b5-1 stipulato il 23 marzo 2025, e che i totali post-trasazione includono 284 azioni acquistate nell’Employee Stock Purchase Plan dell’emittente il 14 maggio 2025. Non sono state riportate operazioni su strumenti derivati o altre modifiche.

El Director Médico de Arcellx, Inc. (ACLX), Heery Christopher, informó ventas de acciones comunes de la compañía bajo un plan de negociación Rule 10b5-1. El 18/09/2025 vendió 3.343 acciones a un precio medio ponderado de $80,0085, quedando con 34.427 acciones en beneficio propio tras esa operación. El 19/09/2025 vendió 300 acciones adicionales a $80,00, quedando 34.127 acciones en beneficio propio. El Formulario 4 fue firmado por un apoderado el 19/09/2025.

La presentación señala que las ventas se realizaron conforme a un plan 10b5-1 celebrado el 23 de marzo de 2025, y que los totales tras la operación incluyen 284 acciones adquiridas bajo el Employee Stock Purchase Plan del emisor el 14 de mayo de 2025. No se reportaron transacciones derivadas ni otros cambios.

아셀릭스(Arcellx, Inc. ACLX)의 CMO인 Heery Christopher가 Rule 10b5-1 거래 계획에 따라 회사 보통주를 매도했다고 보고했습니다. 2025년 9월 18일 3,343주를 가중평균가 $80.0085에 매도하여 거래 후 보유주식이 34,427주가 되었습니다. 2025년 9월 19일에는 추가로 300주를 $80.00에 매도하여 보유주식이 34,127주로 감소했습니다. 4형(Form 4)은 2025년 9월 19일에 대리인이 서명했습니다.

보고서에 따르면 매매는 2025년 3월 23일에 체결된 10b5-1 계획에 따라 이루어졌으며, 거래 후 총계에는 2025년 5월 14일에 발행사가 시행한 2022년 직원주식매수계획(Employee Stock Purchase Plan) 하의 284주가 포함됩니다. 파생상품 거래나 기타 변동은 보고되지 않았습니다.

Le directeur médical d’Arcellx, Inc. (ACLX), Heery Christopher, a déclaré des ventes d’actions ordinaires de la société dans le cadre d’un plan de trading Rule 10b5-1. Le 18/09/2025, il a vendu 3 343 actions à un prix moyen pondéré de 80,0085 $, ce qui l’a laissé avec 34 427 actions détenues après cette transaction. Le 19/09/2025, il a vendu 300 actions supplémentaires à 80,00 $, laissant 34 127 actions détenues. Le Formulaire 4 a été signé par un mandataire le 19/09/2025.

Le dépôt précise que les ventes ont été effectuées en vertu d’un plan 10b5-1 établi le 23 mars 2025 et que les totaux post-transaction incluent 284 actions acquises dans le cadre du Employee Stock Purchase Plan de l’émetteur le 14 mai 2025. Aucune transaction dérivée ni autre changement n’a été signalé.

Der Chief Medical Officer von Arcellx, Inc. (ACLX), Heery Christopher, hat Verkäufe von Unternehmensaktien gemäß einem Rule 10b5-1-Handelsplan gemeldet. Am 18.09.2025 verkaufte er 3.343 Aktien zu einem gewichteten Durchschnittspreis von $80,0085, sodass er nach dieser Transaktion 34.427 Aktien im Eigentum hielt. Am 19.09.2025 verkaufte er weitere 300 Aktien zu $80,00, womit sich sein gehaltenes Aktienvolumen auf 34.127 Aktien reduzierte. Das Formular 4 wurde am 19.09.2025 von einem Bevollmächtigten unterzeichnet.

Der Eintrag vermerkt, dass die Verkäufe im Rahmen eines am 23. März 2025 abgeschlossenen 10b5-1-Plans erfolgten und dass die Post-Transaction-Beträge 284 Aktien umfassen, die am 14. Mai 2025 über den Employee Stock Purchase Plan des Emittenten erworben wurden. Es wurden keine Derivategeschäfte oder sonstige Änderungen gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Heery Christopher

(Last) (First) (Middle)
C/O ARCELLX, INC.
800 BRIDGE PARKWAY

(Street)
REDWOOD CITY CA 94065

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arcellx, Inc. [ ACLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF MEDICAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/18/2025 S(1) 3,343 D $80.0085(2) 34,427(3) D
Common Stock 09/19/2025 S(1) 300 D $80 34,127 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 23, 2025.
2. Represents the weighted average share price of an aggregate total of 3,343 shares sold in the price range of $80.00 to $80.055 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. Includes 284 shares acquired under the Issuer's 2022 Employee Stock Purchase Plan on May 14, 2025.
/s/ Michelle Gilson, as Attorney-in-Fact 09/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ACLX insider Heery Christopher report on Form 4?

He reported the sale of 3,343 shares on 09/18/2025 and 300 shares on 09/19/2025, executed under a Rule 10b5-1 plan.

At what price were the ACLX shares sold by the insider?

The weighted-average price for the 3,343-share sale was $80.0085 and the 300-share sale was at $80.00 per share.

When was the 10b5-1 trading plan established for the ACLX insider?

The Form 4 states the 10b5-1 plan was entered into on March 23, 2025.

How many ACLX shares does the reporting person own after these transactions?

The reporting person beneficially owned 34,427 shares after the 09/18/2025 sale and 34,127 shares after the 09/19/2025 sale.

Do the ownership totals include any recent employee plan purchases?

Yes, the totals include 284 shares acquired under Arcellx's 2022 Employee Stock Purchase Plan on May 14, 2025.
ARCELLX INC

NASDAQ:ACLX

ACLX Rankings

ACLX Latest News

ACLX Latest SEC Filings

ACLX Stock Data

4.34B
45.53M
13.45%
106.11%
12.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
REDWOOD CITY